2-Nonyl-3-methyl-1,4-naphthoquinone | 134650-31-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-Nonyl-3-methyl-1,4-naphthoquinone
• 英文别名: 2-Methyl-3-nonylnaphthalene-1,4-dione
• CAS: 134650-31-0
• 化学式: C₂₀H₂₆O₂
• 分子量: 298.425
• InChiKey: QDUAOKYKHMKPTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  正癸酸 在 ammonium peroxydisulfate 、 silver nitrate 作用下， 以 水 、 乙腈 为溶剂， 反应 0.41h， 生成 2-Nonyl-3-methyl-1,4-naphthoquinone
  参考文献：
  名称：

  Liu, Benli; Gu, Lianquan; Zhang, Jingling, Recueil des Travaux Chimiques des Pays-Bas, 1991, vol. 110, # 4, p. 99 - 103

  摘要：

  DOI：

文献信息

• LIU, BENLI;GU, LIANQUAN, XUACHZHUN SHIFAN DASYUEH SYUEHBAO, 24,(1990) N, S. 43-46
  作者：LIU, BENLI、GU, LIANQUAN

  DOI：——

  日期：——
• TREATMENT OF MITOCHONDRIAL DISEASES WITH NAPHTHOQUINONES
  申请人：Edison Pharmaceuticals, Inc.

  公开号：EP2600857A2

  公开（公告）日：2013-06-12
• [EN] TREATMENT OF MITOCHONDRIAL DISEASES WITH NAPHTHOQUINONES<br/>[FR] TRAITEMENT DE MALADIES MITOCHONDRIALES PAR DES NAPHTOQUINONES
  申请人：EDISON PHARMACEUTICALS INC

  公开号：WO2012019029A2

  公开（公告）日：2012-02-09

  Methods of treating, preventing or suppressing symptoms associated with mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), dominant optic atrophy (DOA); mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Leigh syndrome or Kearns-Sayre Syndrome (KSS) with compounds of Formula (I) are disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods are also disclosed.
• [EN] THERAPEUTIC COMPOSITIONS INCLUDING NAPHTHOQUINONES AND USES THEREOF<br/>[FR] COMPOSITIONS THÉRAPEUTIQUES COMPRENANT DES NAPHTHOQUINONES ET LEURS UTILISATIONS
  申请人：STEALTH PEPTIDES INT INC

  公开号：WO2015183985A2

  公开（公告）日：2015-12-03

  Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of naphthoquinones, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to naphthoquinones and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2',6'-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2',6'-Dmt-Lys-Phe-NH2.
• Liu, Benli; Gu, Lianquan; Zhang, Jingling, Recueil des Travaux Chimiques des Pays-Bas, 1991, vol. 110, # 4, p. 99 - 103
  作者：Liu, Benli、Gu, Lianquan、Zhang, Jingling

  DOI：——

  日期：——